Sophia H L George1,2,3, Talia Donenberg2,3,4, Cheryl Alexis5, Vincent DeGennaro6, Hedda Dyer7, Sook Yin8, Jameel Ali9, Raleigh Butler10, Sheray N Chin11, DuVaughn Curling10, Dwight Lowe11, John Lunn10, Theodore Turnquest10, Gilian Wharfe11, Danielle Cerbon2,12, Priscila Barreto-Coelho2,12, Matthew P Schlumbrecht1,2,3, Mohammad R Akbari13, Steven A Narod13, Judith E Hurley2,3,12. 1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami, Miami, Florida. 2. Sylvester Comprehensive Cancer Center, Miami, Florida. 3. Leonard Miller School of Medicine, University of Miami, Miami, Florida. 4. Department of Genetics, University of Miami, Miami, Florida. 5. Faculty of Medical Sciences, University of West Indies-Cave Hill, Barbados. 6. Innovation Health International, Haiti. 7. Ross University School of Medicine, Commonwealth of Dominica (now in Barbados). 8. Cayman Islands Cancer Society, Grand Cayman, Cayman Islands. 9. St. James Medical Complex, Northwest Regional Health Authority, Port-of-Spain, Trinidad and Tobago. 10. Princess Margaret Hospital, University of the West Indies, School of Clinical Medicine and Research, Nassau, Bahamas. 11. Department of Pathology, University of West Indies-Mona, Kingston, Jamaica. 12. Division of Medical Oncology, Department of Medicine, University of Miami, Miami, Florida. 13. Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Canada.
Abstract
Importance: Rates of breast and ovarian cancer are high in the Caribbean; however, to date, few published data quantify the prevalence of inherited cancer in the Caribbean population. Objective: To determine whether deleterious variants in genes that characterize the hereditary breast and ovarian cancer syndrome are associated with the development of breast and ovarian cancer in the English- and Creole-speaking Caribbean populations. Design, Setting, and Participants: This multisite genetic association study used data from germline genetic test results between June 2010 and June 2018 in the Bahamas, Cayman Islands, Barbados, Dominica, Jamaica, Haiti, and Trinidad and Tobago. Next-generation sequencing on a panel of 30 genes and multiplex ligation-dependent probe amplification (BRCA1 and BRCA2) were performed. Medical records were reviewed at time of study enrollment. Women and men diagnosed with breast and ovarian cancer with at least 1 grandparent born in the participating study sites were included; 1018 individuals were eligible and consented to participate in this study. Data were analyzed from November 4, 2019, to May 6, 2020. Exposures: Breast and/or ovarian cancer diagnosis. Main Outcomes and Measures: Rate of inherited breast and ovarian cancer syndrome and spectrum and types of variants. Results: Of 1018 participants, 999 (98.1%) had breast cancer (mean [SD] age, 46.6 [10.8] years) and 21 (2.1%) had ovarian cancer (mean [SD] age, 47.6 [13.5] years). Three individuals declined to have their results reported. A total of 144 of 1015 (14.2%) had a pathogenic or likely pathogenic (P/LP) variant in a hereditary breast and ovarian cancer syndrome gene. A total of 64% of variant carriers had P/LP variant in BRCA1, 23% in BRCA2, 9% in PALB2 and 4% in RAD51C, CHEK2, ATM, STK11 and NBN. The mean (SD) age of variant carriers was 40.7 (9.2) compared with 47.5 (10.7) years in noncarriers. Individuals in the Bahamas had the highest proportion of hereditary breast and ovarian cancer (23%), followed by Barbados (17.9%), Trinidad (12%), Dominica (8.8%), Haiti (6.7%), Cayman Islands (6.3%), and Jamaica (4.9%). In Caribbean-born women and men with breast cancer, having a first- or second-degree family member with breast cancer was associated with having any BRCA1 or BRCA2 germline variant (odds ratio, 1.58; 95% CI, 1.24-2.01; P < .001). A BRCA1 vs BRCA2 variant was more strongly associated with triple negative breast cancer (odds ratio, 6.33; 95% CI, 2.05-19.54; P = .001). Conclusions and Relevance: In this study, among Caribbean-born individuals with breast and ovarian cancer, 1 in 7 had hereditary breast and ovarian cancer. The proportion of hereditary breast and ovarian cancer varied by island and ranged from 23% in the Bahamas to 4.9% in Jamaica. Each island had a distinctive set of variants.
Importance: Rates of breast and ovarian cancer are high in the Caribbean; however, to date, few published data quantify the prevalence of inherited cancer in the Caribbean population. Objective: To determine whether deleterious variants in genes that characterize the hereditary breast and ovarian cancer syndrome are associated with the development of breast and ovarian cancer in the English- and Creole-speaking Caribbean populations. Design, Setting, and Participants: This multisite genetic association study used data from germline genetic test results between June 2010 and June 2018 in the Bahamas, Cayman Islands, Barbados, Dominica, Jamaica, Haiti, and Trinidad and Tobago. Next-generation sequencing on a panel of 30 genes and multiplex ligation-dependent probe amplification (BRCA1 and BRCA2) were performed. Medical records were reviewed at time of study enrollment. Women and men diagnosed with breast and ovarian cancer with at least 1 grandparent born in the participating study sites were included; 1018 individuals were eligible and consented to participate in this study. Data were analyzed from November 4, 2019, to May 6, 2020. Exposures: Breast and/or ovarian cancer diagnosis. Main Outcomes and Measures: Rate of inherited breast and ovarian cancer syndrome and spectrum and types of variants. Results: Of 1018 participants, 999 (98.1%) had breast cancer (mean [SD] age, 46.6 [10.8] years) and 21 (2.1%) had ovarian cancer (mean [SD] age, 47.6 [13.5] years). Three individuals declined to have their results reported. A total of 144 of 1015 (14.2%) had a pathogenic or likely pathogenic (P/LP) variant in a hereditary breast and ovarian cancer syndrome gene. A total of 64% of variant carriers had P/LP variant in BRCA1, 23% in BRCA2, 9% in PALB2 and 4% in RAD51C, CHEK2, ATM, STK11 and NBN. The mean (SD) age of variant carriers was 40.7 (9.2) compared with 47.5 (10.7) years in noncarriers. Individuals in the Bahamas had the highest proportion of hereditary breast and ovarian cancer (23%), followed by Barbados (17.9%), Trinidad (12%), Dominica (8.8%), Haiti (6.7%), Cayman Islands (6.3%), and Jamaica (4.9%). In Caribbean-born women and men with breast cancer, having a first- or second-degree family member with breast cancer was associated with having any BRCA1 or BRCA2 germline variant (odds ratio, 1.58; 95% CI, 1.24-2.01; P < .001). A BRCA1 vs BRCA2 variant was more strongly associated with triple negative breast cancer (odds ratio, 6.33; 95% CI, 2.05-19.54; P = .001). Conclusions and Relevance: In this study, among Caribbean-born individuals with breast and ovarian cancer, 1 in 7 had hereditary breast and ovarian cancer. The proportion of hereditary breast and ovarian cancer varied by island and ranged from 23% in the Bahamas to 4.9% in Jamaica. Each island had a distinctive set of variants.
Authors: Babatunde Adedokun; Yonglan Zheng; Paul Ndom; Antony Gakwaya; Timothy Makumbi; Alicia Y Zhou; Toshio F Yoshimatsu; Alex Rodriguez; Ravi K Madduri; Ian T Foster; Aminah Sallam; Olufunmilayo I Olopade; Dezheng Huo Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-23 Impact factor: 4.254
Authors: Deborah Cragun; Anne Weidner; Courtney Lewis; Devon Bonner; Jongphil Kim; Susan T Vadaparampil; Tuya Pal Journal: Cancer Date: 2017-02-09 Impact factor: 6.860
Authors: Rachel E Rosenblum; Celina Ang; Sabrina A Suckiel; Emily R Soper; Meenakshi R Sigireddi; Sinead Cullina; Gillian M Belbin; Aimee L Lucas; Eimear E Kenny; Noura S Abul-Husn Journal: JCO Precis Oncol Date: 2020-11-23
Authors: M Trottier; J Lunn; R Butler; D Curling; T Turnquest; W Francis; D Halliday; R Royer; S Zhang; S Li; I Thompson; T Donenberg; J Hurley; M R Akbari; S A Narod Journal: Clin Genet Date: 2015-05-31 Impact factor: 4.438
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Noura S Abul-Husn; Emily R Soper; Jacqueline A Odgis; Sinead Cullina; Dean Bobo; Arden Moscati; Jessica E Rodriguez; Ruth J F Loos; Judy H Cho; Gillian M Belbin; Sabrina A Suckiel; Eimear E Kenny Journal: Genome Med Date: 2019-12-31 Impact factor: 11.117
Authors: G A Yanus; E L Savonevich; A P Sokolenko; A A Romanko; V I Ni; E Kh Bakaeva; O A Gorustovich; I V Bizin; E N Imyanitov Journal: Fam Cancer Date: 2022-05-21 Impact factor: 2.375
Authors: Shawn M Hercules; Xiyu Liu; Blessing B I Bassey-Archibong; Desiree H A Skeete; Suzanne Smith Connell; Adetola Daramola; Adekunbiola A Banjo; Godwin Ebughe; Thomas Agan; Ima-Obong Ekanem; Joe Udosen; Christopher Obiorah; Aaron C Ojule; Michael A Misauno; Ayuba M Dauda; Ejike C Egbujo; Jevon C Hercules; Amna Ansari; Ian Brain; Christine MacColl; Yili Xu; Yuxin Jin; Sharon Chang; John D Carpten; André Bédard; Greg R Pond; Kim R M Blenman; Zarko Manojlovic; Juliet M Daniel Journal: Cancer Causes Control Date: 2022-04-06 Impact factor: 2.532